Integratori per combattere i disturbi depressivi, bibliografia

In alcuni casi di depressione, alimentazione e integrazione nutrizionale corrette possono essere un valido aiuto sia da sole sia in supporto a farmaci e sostegno psicologico.

Luca Pennisi, Integratori per combattere i disturbi depressivi, Farmacia news n. 4, 2013, pag. 34

Bibliografia

  1. Argyropoulos SV, Hood SD, Adrover M et al: Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol Psychiatry 2004 Oct 1;56(7):503-9.
  2. Evans L, Golshan S, Kelsoe J et al: Effects of rapid tryptophan depletion on sleep electroencephalogram and mood in subjects with partially remitted depression on bupropion. Neuropsychopharmacology 2002 Dec;27(6):1016-26.
  3. Levitan RD, Shen JH, Jindal R et al: Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. J Psychiatry Neurosci. 2000 Sep;25(4):337-46.
  4. Song C, Lin A, Bonaccorso S et al: The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord. 1998 Jun;49(3):211-9.
  5. Eby GA 3rd, Eby KL: Magnesium for treatment-resistant depression: a review and hyphotesis. Med Hyphotesis 2010 Apr;74(4):649-90.
  6. Eby Ga, Eby KL: Rapid recovery from major depression using magnesium treatment. Med Hyphotesis 2006;67(2):362-70.
  7. Nechifor M: Magnesium in major depression. Magnesium Res. 2009 Sep;22(3):163S-166S.
  8. Annweiler C, Schott AM, Rolland Y, et al: Dietary intake of vitamin D and cognition in older women: a large population-based study. Neurology 2010 Nov 16;75(20):1810-6.
  9. Hoogendijk WJ, Lips P, Dik MG, et al: Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry 2008 May;65(5):508-12.
  10. Janicak PG, Lipinski JD, Comaty JE, et al: S-adenosylmethionine: a literature review and preliminary report. Ala J     Med Sci. 1988;25:306-13.
  11. Bressa GM: S-adenosyl-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand. 1994;154:7-14.
  12. Brown R, Gerbarg P, Bottiglieri T: S-adenosylmethionine in the clinical practice of psychiatry, neurology and internal medicine. Clin Pract Intern Med. 2000;1:230-41.
  13. Otero-Losado ME, Rubio MC: Acute effects of S-adenosyl-methionine on catecholaminergic central function. Eur J Pharmacol. 1989;163:353-6.
  14. Otero-Losado ME, Rubio MC: Acute changes in 5HT metabolism after S-adenosyl-methionine administration. Gen Pharmacol. 1989;20-403-6.
  15. Delle Chiaie R, Pancheri P, Scapicchio P: Efficacy and tolerability of orale and intramuscolar S-adenosyl-L-methionine 1,4 butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr. 2002 Nov;76(5):1172S-6S.
  16. Pancheri P, Scapicchio P, Chiaie RD: A double blind, randomized parallel-group, efficacy and safety study of intramuscolar S-adenosyl-L-methionine 1,4 butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int Neuropsychopharmacol. 2002 Dec;5(4):287-94.
  17. Goren JL, Stoll AL, Damico KE, et al: Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy 2004 Nov;24(11):1501-7.

ARTICOLI CORRELATIALTRO DALL'AUTORE